



Larotrectinib (LOXO-101, ARRY-470)

A0685

This month's MOTM is Larotrectinib (LOXO-101, ARRY-470). Discovered by Array BioPharma and licensed to Loxo Oncology in 2013, Larotrectinib is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC, which is now a phase II candidate for the treatment of cancer.

LCC's process chemistry team have developed a highly efficient synthetic route that provides access to Larotrectinib in >98% ee (>95% de) and has already been piloted on kilogram scale. As a result, LCC can also provide the intermediates to aid analogue synthesis.

LCC will continue to apply its expertise in catalysis and chiral chemistry to produce building blocks, key intermediates and API. If you are interested in similar products and feel you could benefit from our services, I'd be delighted to talk with you.

Best Wishes,

Dr Paul Colbon

CEO & Co-Founder

Office: +44(0)151 794 2936 | Mobile: +44(0)7415946636

Email: paul.colbon@liverpoolchirochem.co.uk



bionow.
MEMBER



UK Trade
& Investment



BUILDING BLOCKS



SCREENING
LIBRARIES



CHEMISTRY
SERVICES



MOLFINDER